From: Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer
Factor | YKL-40 detected | YKL-40 not detected | p |
---|---|---|---|
Mean/median tumor size (range) | 4.0 cm/3.0 cm (0 – 20.0) | 2.7 cm/2.3 cm (0 – 16.0) | <.05 |
Tumor differentiation*, N (%) | Â | Â | <.001 |
   • Well | 1 (2) | 17 (24) |  |
   • Moderate | 8 (22) | 25 (35) |  |
   • Poor | 20 (54) | 9 (12) |  |
   • Unknown | 8 (22) | 21 (29) |  |
ER status*, N (%) | Â | Â | <.01 |
   • Negative | 21 (57) | 19 (27) |  |
   • Positive | 15 (41) | 52 (72) |  |
   • Unknown/Not done | 1 (2) | 1 (1) |  |
PR status*, N (%) | Â | Â | <.01 |
   • Negative | 26 (71) | 25 (35) |  |
   • Positive | 10 (27) | 46 (64) |  |
   • Unknown/Not done | 1 (2) | 1 (1) |  |
Nodal status, N (%) | Â | Â | NS |
   • Negative | 18 (49) | 32 (44) |  |
   • Positive | 19 (51) | 40 (56) |  |
Mean/median # of positive nodes (Node-positive patients only) | 4.8/2.0 (1 – 22) | 3.1/2.0 (1 – 17) | NS |
Her2*, N (%) | Â | Â | NS |
   • Negative | 27 (73) | 47 (65) |  |
   • Positive | 8 (22) | 21 (29) |  |
   • Unknown/Not done | 2 (5) | 4 (6) |  |
T stage, N (%) | Â | Â | NS |
   • T1 | 10 (27) | 33 (46) |  |
   • T2 | 17 (46) | 30 (42) |  |
   • T3 | 4 (11) | 5 (7) |  |
   • T4 | 6 (16) | 4 (5) |  |
N stage, N (%) | Â | Â | NS |
   • N0 | 18 (49) | 33 (46) |  |
   • N1 | 11 (30) | 30 (41) |  |
   • N2 | 7 (19) | 7 (10) |  |
   • N3 | 1 (2) | 2 (3) |  |
AJCC stage, N (%) | Â | Â | NS |
   • I | 6 (16) | 16 (22) |  |
   • IIA | 11 (30) | 28 (39) |  |
   • IIB | 6 (16) | 15 (21) |  |
   • IIIA | 7 (19) | 7 (10) |  |
   • IIIB | 5 (14) | 4 (6) |  |
   • IIIC | 2 (5) | 1 (1) |  |
   • IV | 0 (0) | 1 (1) |  |